ReCode Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--Jan 3, 2023--
ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that Shehnaaz Suliman, M.D., M.B.A., M.Phil., Chief Executive Officer of ReCode Therapeutics, will present a company overview at 9:00 a.m. PT on Tuesday, January 10, 2023 at the 41st Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA.
About ReCode Therapeutics
ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics. ReCode’s lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. ReCode is leveraging its SORT LNP platform and nucleic acid technologies to expand its pipeline with therapeutics that use mRNA-mediated replacement and gene correction in target organs with precision targeting of disease-relevant cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and on LinkedIn.
View source version on businesswire.com:https://www.businesswire.com/news/home/20230103005189/en/
CONTACT: Investor Contact:
The Grace Communication Group
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL GENERAL HEALTH HEALTH HEALTH TECHNOLOGY GENETICS
SOURCE: ReCode Therapeutics
Copyright Business Wire 2023.
PUB: 01/03/2023 08:00 AM/DISC: 01/03/2023 08:01 AM